Bhargava Vinay, Greg Mark E, Shields Mark C
Advocate Physician Partners, Mount Prospect, Illinois 60056, USA.
J Manag Care Pharm. 2010 Jul-Aug;16(6):384-92. doi: 10.18553/jmcp.2010.16.6.384.
Generic dispensing ratio (GDR) is an important measure of efficiency in pharmacy benefit management. A few studies have examined the effects of academic detailing or generic drug samples on GDR. On July 1, 2007, a physician-hospital organization (PHO) with a pay-for-performance incentive for generic utilization initiated a pilot generic medication voucher program that augmented its existing pharmacist-led academic detailing efforts. No published studies have examined the role of generic medication vouchers in promoting generic drug utilization.
To determine if supplementing an existing academic detailing initiative in a PHO with a generic medication voucher program would be more effective in increasing the GDR compared with academic detailing alone.
The intervention took place over the 9-month period from July 1, 2007, through March 31, 2008. Vouchers provided patients with the first fill of a 30-day supply of a generic drug at no cost to the patient for 8 specific generic medications obtained through a national community pharmacy chain. The study was conducted in a PHO composed of 7 hospitals and approximately 2,900 physicians (900 primary care providers [PCPs] and 2,000 specialists). Of the approximately 300 PCP practices, 21 practices with at least 2 physicians each were selected on the basis of high prescription volume (more than 500 pharmacy claims for the practice over a 12-month pre-baseline period) and low GDR (practice GDR less than 55% in the 12-month pre-baseline period). These 21 practices were then randomized to a control group of academic detailing alone or the intervention group that received academic detailing plus generic medication vouchers. One of 10 intervention groups declined to participate, and 2 of 11 control groups dropped out of the PHO. GDR was calculated monthly for all pharmacy claims including the 8 voucher medications. GDR was defined as the ratio of the total number of paid generic pharmacy claims divided by the total number of paid pharmacy claims for 108 prescriber identification numbers (Drug Enforcement Administration [DEA] or National Provider Identifier [NPI]) for 9 intervention groups [n = 53 PCPs] and 9 control groups [n = 55 PCPs]). For both intervention and control arms, the GDR for each month from July 2007 (start of 2007 Q3, intervention start date) through September 2008 (end of 2008 Q3, 6 months after intervention end date) was compared with the same month in the previous year. A descriptive analysis compared a 9-month baseline period from 2006 Q3 through 2007 Q1 with a 9-month voucher period from 2007 Q3 to 2008 Q1. A panel data regression analysis assessed GDR for 18 practices over 27 months (12 months pre-intervention and 15 months post-intervention).
A total of 656 vouchers were redeemed over the 9-month voucher period from July 1, 2007, through March 31, 2008, for an average of about 12 vouchers per participating physician; approximately one-third of the redeemed vouchers were for generic simvastatin. The GDR increase for all drugs, including the 8 voucher drugs, was 7.4 points for the 9 PCP group practices with access to generic medication vouchers, from 53.4% in the 9-month baseline period to 60.8% in the 9-month voucher period, compared with a 6.2 point increase for the control group from 55.9% during baseline to 62.1% during the voucher period. The panel data regression model estimated that the medication voucher program was associated with a 1.77-point increase in overall GDR compared with academic detailing alone (P = 0.047).
Compared with academic detailing alone, a generic medication voucher program providing a 30-day supply of 8 specific medications in addition to academic detailing in PCP groups with low GDR and high prescribing volume in an outpatient setting was associated with a small but statistically significant increase in adjusted overall GDR.
通用药品配给率(GDR)是药房效益管理中一项重要的效率衡量指标。一些研究已经考察了学术推广或通用药品样品对GDR的影响。2007年7月1日,一个对通用药品使用实行绩效薪酬激励的医师-医院组织(PHO)启动了一项通用药品代金券试点项目,该项目强化了其现有的由药剂师主导的学术推广工作。尚无已发表的研究考察通用药品代金券在促进通用药品使用方面的作用。
确定在PHO中,用通用药品代金券项目补充现有的学术推广举措,与单纯的学术推广相比,在提高GDR方面是否更有效。
干预从2007年7月1日至2008年3月31日持续9个月。代金券为患者提供通过全国社区药房连锁获得的8种特定通用药品30天用量的首次配药,患者无需付费。该研究在一个由7家医院和大约2900名医师(900名初级保健提供者[PCP]和2000名专科医生)组成的PHO中进行。在大约300个PCP诊所中,根据高处方量(在基线前12个月期间该诊所超过500份药房报销申请)和低GDR(基线前12个月期间诊所GDR低于55%),选择了21个每个至少有2名医师的诊所。然后将这21个诊所随机分为单纯学术推广的对照组或接受学术推广加通用药品代金券的干预组。10个干预组中有1个拒绝参与,11个对照组中有2个退出了PHO。对包括8种代金券药品在内的所有药房报销申请每月计算GDR。GDR定义为支付的通用药房报销申请总数除以108个开处方者识别号(药品执法管理局[DEA]或国家提供者识别号[NPI])的支付药房报销申请总数,涉及9个干预组[53名PCP]和9个对照组[55名PCP])。对于干预组和对照组,将2007年7月(2007年第三季度开始,干预开始日期)至2008年9月(2008年第三季度结束,干预结束日期后6个月)每个月的GDR与上一年同月进行比较。描述性分析将2006年第三季度至2007年第一季度的9个月基线期与2007年第三季度至2008年第一季度的9个月代金券期进行比较。面板数据回归分析评估了18个诊所在27个月(干预前12个月和干预后15个月)的GDR。
在2007年7月1日至2008年3月31日的9个月代金券期内,共兑换了656张代金券,平均每位参与的医师约12张;约三分之一的兑换代金券是用于通用辛伐他汀。对于所有药物,包括8种代金券药物,9个有通用药品代金券的PCP组诊所的GDR增加了7.4个百分点,从9个月基线期的53.4%增至9个月代金券期的60.8%,而对照组从基线期的55.9%增至代金券期的62.1%,增加了6.2个百分点。面板数据回归模型估计,与单纯的学术推广相比,药品代金券项目使总体GDR增加了1.77个百分点(P = 0.047)。
在门诊环境中,对于GDR低且处方量高的PCP组,与单纯的学术推广相比